Latest Earnings Results: Q3 '26
Estimated EPS
-$1.51
Reported EPS
-$1.33
Surprise
+12.07%
Estimated Rev
$0.91M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$1.21 down -55.13% YoY • Celcuity expects research and development and selling, general and administrative expenses to increase as REVTORPYK commercialization ramps up and trials continue; Celcuity believes current cash resources will fund operations through 2029.
Bullish Takeaway
Celcuitys REVTORPYK received FDA approval and a preferred Category 1 NCCN recommendation; VIKTORIA-1 PIK3CA-mutant results reported median PFS of 11.1 months versus 5.6 months, and cash resources support operations through 2029.
Bearish Takeaway
Celcuitys quarterly net loss reached $73.3M as SG&A rose; competitors and reimbursement constraints threaten commercialization, while operating cash use and uncertain access to future capital add financing risk.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$1.35 | -- | -- | N/A |
Q3 '26 | -$1.51 | -$1.33 | 12.07% | BEAT |
Q2 '26 | -$1.16 | -$1.44 | -23.65% | MISSED |
Q1 '26 | -$1.05 | -$0.97 | 7.95% | BEAT |
Q4 '25 | -$1.04 | -$0.97 | 6.92% | BEAT |